Clinical applications of melanoma genetics

Current Treatment Options in Oncology

Volumn 15, Issue 2, 2014, Pages 336-350

  Gabree, Michele ^a   Patel, Devanshi ^a   Rodgers, Linda ^a  

^a NONE   (United States)

Author keywords

CDK4; CDKN2A; Genetic counseling; Hereditary; MC1R; Melanoma; Skin cancer surveillance

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE INHIBITOR 2A; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; MELANOCORTIN 1 RECEPTOR; MICROPHTHALMIA ASSOCIATED TRANSCRIPTION FACTOR; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN P53;

ARTICLE; BAP1 GENE; CANCER EPIDEMIOLOGY; CANCER GENETICS; CANCER INCIDENCE; CANCER SCREENING; CANCER SURVIVAL; CANCER SUSCEPTIBILITY; CUTANEOUS MELANOMA; DYSPLASTIC NEVUS; ETHNIC DIFFERENCE; FAMILIAL CANCER; FAMILY HISTORY; GENE FREQUENCY; GENE MUTATION; GENETIC ASSOCIATION; GENETIC COUNSELING; GENETIC SCREENING; GERMLINE MUTATION; HAMARTOMA; HEREDITY; HUMAN; MALIGNANT TRANSFORMATION; MELANOCYTE; MELANOMA; ONSET AGE; PANCREAS CANCER; PATHOGENESIS; PEDIGREE; PENETRANCE; PROTEIN FUNCTION; RISK ASSESSMENT; RISK FACTOR; SOCIAL PSYCHOLOGY; SUN EXPOSURE; TUMOR GENE; XERODERMA PIGMENTOSUM; GENETICS; MUTATION; PRACTICE GUIDELINE; PSYCHOLOGY; SKIN NEOPLASMS;

CYCLIN-DEPENDENT KINASE INHIBITOR P16; GENETIC COUNSELING; GENETIC TESTING; HUMANS; MELANOMA; MUTATION; PEDIGREE; PRACTICE GUIDELINES AS TOPIC; RECEPTOR, MELANOCORTIN, TYPE 1; RISK FACTORS; SKIN NEOPLASMS;

EID: 84902375725     PISSN: 15272729     EISSN: 15346277     Source Type: Journal    
DOI: 10.1007/s11864-014-0282-8     Document Type: Article

References (66)

1. Goldstein A, Chan M, Harland M, Hayward N, Demenais F, Bishop DT, et al. Features associated with germline CDKN2A mutations: a GenoMEL study of melanoma-prone families from three continents. J Med Genet. 2007;44:99-106.
2. Bishop DT, Demenais F, Goldstein A, Bergman W, Bishop J, Bressac-de Paillerets B, et al. Geographical variation in the penetrance of CDKN2A mutations for melanoma. J Natl Cancer Inst. 2002;94:894-903. (Pubitemid 34778088)
3. Leachman S, Carucci J, Kohlmann L, Banks K, Asgari M, Bergman W, et al. Selection criteria for genetic assessment of patients with familial melanoma. J Am Acad Dermatol. 2009;61:677.e1-14.
4. Njauw CNJ, Kim I, Piris A, Gabree M, Taylor M, Lane AM, et al. Germline BAP1 inactivation is preferentially associated with metastatic ocular melanoma and cutaneous-ocular melanoma families. PLoS One. 2012;7:e35295.
5. Pilarski R, Burt R, Kohlman W, Pho L, Shannon KM, Swisher E. Cowden syndrome and the PTEN hamartoma tumor syndrome: systematic review and revised diagnostic criteria. J Natl Cancer Inst. 2013;105:1607-16.
6. Monnerat C, Chompret A, Kannengiesser C, Avril M, Janin N, Spatz A, et al. BRCA1, BRCA2, TP53, and CDKN2A germline mutations in patients with breast cancer and cutaneous melanoma. Fam Cancer. 2007;6:453-61. (Pubitemid 47622260)
7. Cruz C, Teule A, Caminal J, Blanco I, Piulats J. Uveal melanoma and BRCA1/BRCA2 genes: a relationship that needs further investigation. J Clin Oncol. 2011;29:e827-9.
8. Curiel-Lewandrowski C, Curiel-Lewandrowski C, Speetzen L, Cranmer L, Warneke J, Loescher L. Multiple primary cutaneous melanomas in Li-Fraumeni syndrome. Arch Dermatol. 2011;147:248-50.
9. Goldstein A, Chan M, Harland M, Gillanders E, Hayward N, Avril M, et al. High-risk melanoma susceptibility genes and pancreatic cancer, neural system tumors, and uveal melanoma across GenoMEL. Cancer Res. 2006;66:9818-28. (Pubitemid 44672032)
10. Bertolotto C, Lesuer F, Giuliano S, Strub T, de Lichy M, Bille K, et al. A SUMOylation-defective MITF germline mutation predisposes to melanoma and renal carcinoma. Nature. 2011;480:94-8.
11. Bradford P, Goldstein A, Tamura D, Khan S, Ueda T, Boyle J, et al. Cancer and neurologic degeneration in xeroderma pigmentosum: long term follow-up characterises the role of DNA repair. J Med Genet. 2011;48:168-76.
12. SEER fact sheets: melanoma of the skin. National Cancer Institute Surveillance, Epidemiology, and End Results Program. From: http://seer.cancer. gov/statfacts/html/melan.html. Accessed 20 Dec 2013.
13. Balch CM, Buzaid AC, Soong SJ, Atkins MB, Cascinelli N, Coit DG, et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol. 2001;19:3635-48. (Pubitemid 32786276)
14. Austin MT, Xing Y, Hayes-Jordan AA, Lally KP, Cormier JN. Melanoma incidence rises for children and adolescents: an epidemiologic review of pediatric melanoma in the United States. J Pediatr Surg. 2013;48(11):2207-13.
15. Erdmann F, Lortet-Tieulen J, Schuz J, Zeeb H, Greinert R, Breitbar EW, et al. International trends in the incidence of malignant melanoma 1953-2008-are recent generations at higher or lower risk? Int J Cancer. 2013;132(2):385-400.
16. Gandini S, Sera F, Cattaruzz MS, Pasquini P, Abeni D, Boyle P, et al. Meta-analysis of risk factors for cutaneous melanoma: I. Common and atypical naevi. Eur J Cancer. 2005;41(1):28-44. (Pubitemid 40029657)
17. Gandini S, Sera F, Cattaruzza MS, Pasquini P, Picconi O, Boyle P, et al. Meta-analysis of risk factors for cutaneous melanoma: II. Sun exposure. Eur J Cancer. 2005;41(1):45-60. (Pubitemid 40029658)
18. Gandini S, Sera F, Cattaruzza MS, Pasquini P, Zanetti R, Masini C, et al. Meta-analysis of risk factors for cutaneous melanoma: III. Family history, actinic damage and phenotypic factors. Eur J Cancer. 2005;41(14):2040-59. (Pubitemid 41337946)
19. Goldstein A, Tucker M. Dysplastic nevi and melanoma. Cancer Epidemiol Biomarkers Prev. 2013;22:528 -32.
20. Crombie IK. Variation of melanoma incidence with latitude in North America and Europe. Br J Cancer. 1979;40:774-81. (Pubitemid 10204798)
21. Whiteman DC, Watt P, Purdie DM, Hughes MC, Hayward NK, Green AC. Melanocytic nevi, solar keratoses, and divergent pathways to cutaneous melanoma. J Natl Cancer Inst. 2003;95:806-12. (Pubitemid 36798427)
22. •• van der Ree J, Krijnen P, Gruis N, de Snoo F, Vasen H, Putter H, et al. Clinical and histologic characteristics of malignant melanoma in families with a germline mutation in CDKN2A. J Am Acad Dermatol. 2011;65:281-8. This study of CDKN2A phenotypes examined individuals in the Netherlands with a founder CDKN2A mutation (p16-Leiden). Consistent with other studies of CDKN2A mutation carriers, this study found younger age of onset and a greater number of individuals with multiple primary melanomas in individuals with CDKN2A mutations versus controls. They also report histological differences, including more superficial spreading and less nodular and lentiginous melanomas, in CDKN2A mutation carriers versus the control group. They conclude that their findings support that melanomas in individuals with CDKN2A mutations develop through a different pathway than later-onset, sporadic melanomas.
23. Goldstein AM. Familial melanoma, pancreatic cancer and germline CDKN2A mutations. Hum Mutat. 2004;23(6):630.
24. McKenzie HA, Fung C, Becker TM, Irvine M, Mann GJ, Kefford RF, et al. Predicting functional significance of cancer-associated p16(INK4a) mutations in CDKN2A. Hum Mutat. 2010;31(6):692-701.
25. Sheppard KE, McArthur GA. The cell-cycle regulator CDK4: an emerging therapeutic target in melanoma. The cell-cycle regulator CDK4: an emerging therapeutic target in melanoma. Clin Cancer Res. 2013;19(19):5320-8.
26. •• Puntervoll H, Yang X, Vetti H, Bachmann I, Avril M, Benfodda M, et al. Melanoma prone families with CDK4 germline mutation: phenotypic profile and associations with MC1R variants. J Med Genet. 2013;50:264-70. This study describes characteristics of individuals with inherited mutations in CDK4. The authors note that germline CDK4 mutations are rare. They conclude that the phenotype of individuals with inherited CDK4 mutations, which includes younger than average age of melanoma onset, multiple primary melanomas, multiple relatives with melanoma, and relatives with pancreatic cancer, is similar to the phenotype of individuals with CDKN2A germline mutations.
27. Cust A, Goumas C, Vuong K, Davies J, Barrett J, Holland E, et al. MC1R genotype as a predictor of early-onset melanoma, compared with self-reported and physician-measured traditional risk factors: an Australian case-control-family study. BMC Cancer. 2013;4:406.
28. Mitra D, Luo X, Morgan A, Wang J, Hoang M, Lo J, et al. An ultraviolet-radiation-independent pathway to melanoma carcinogenesis in the red hair/fair skin background. Nature. 2012;491:449-53.
29. Begg C, Orlow I, Hummer A, Armstrong B, Kricker A, Marrett L, et al. Lifetime risk of melanoma in CDKN2A mutation carriers in a population-based sample. 2005;97:1507-15.
30. •• Maubec E, Chaudru V, Mohamdi H, Blondel C, Margaritte-Jeannin P, Forget S, et al. Familial melanoma: clinical factors associated with germline CDKN2A mutations according to the number of patients affected by melanoma in a family. J Am Acad Dermatol. 2012;67:1257-64. This study examines the correlation between the number of relatives affected with melanoma and CDKN2A mutation status in a French cohort. In the context of the study, the authors also review the features associated with CDKN2A mutation status. The results of this study reveal that a greater number of relatives with melanoma correlate to a higher probability of having a germline CDKN2A mutation.
31. Tsao H, Zhang X, Kwitkiwski L, Finkelstein D, Sober A, Haluska F. Low prevalence of germline CDKN2A and CDK4 mutations in patients with early-onset melanoma. Arch Dermatol. 2000;136:1118-22.
32. Pedace L, De Simone P, Castori M, Sperduti I, Silipo V, Eibenschutz L, et al. Clinical features predicting identification of CDKN2A mutations in Italian patients with familial cutaneous melanoma. Cancer Epidemiol. 2011;35:e116-20.
33. Blackwood MA, Holmes R, Synnestvedt M, Young M, George C, Yang H, et al. Multiple primary melanoma revisited. Cancer. 2002;94:2248-55. (Pubitemid 34411984)
34. Monzon J, Liu L, Brill H, Goldstein A, Tucker M, From L, et al. CDKN2A mutations in multiple primary melanomas. N Engl J Med. 1998;338:879-87. (Pubitemid 28135965)
35. Nikolaou V, Kang X, Stratigos A, Gogas H, Latorre MC, Gabree M, et al. Comprehensive mutational analysis of CDKN2A and CDK4 in Greek patients with cutaneous melanoma. Br J Dermatol. 2011;165:1219-22.
36. Whiteman D, Milligan A, Welch J, Green A, Hayward N. Germline CDKN2A mutations in childhood melanoma. JNCI. 1997;89(19):1460.
37. Berg P, Wennberg A-M, Tuominen R, Sander B, Rozell B, Platz A, et al. Germline CDKN2A mutations are rare in child and adolescent cutaneous melanoma. Melanoma Res. 2004;14(4):251-5. (Pubitemid 39159136)
38. de Snoo F, Bishop DT, Bergman B, van Leeuwen I, van der Drift C, van Nieuwpoort F, et al. Increased risk of cancer other than melanoma in CDKN2A founder mutation (p16-Leiden)-positive melanoma families. Clin Cancer Res. 2008;14:7151-7.
39. Harinck F, Kluijt I, van der Stoep N, Oldenburg R, Wagner A, Aalfs C, et al. Indication for CDKN2Amutation analysis in familial pancreatic cancer families without melanomas. J Med Genet. 2012;49:362-5.
40. Ghiorzo P, Fornarini G, Sciallero S, Battistuzzi L, Belli F, Bernard L, et al. CDKN2A is the main susceptibility gene in Italian pancreatic cancer families. J Med Genet. 2012;49:164-70.
41. McWilliams R, Wieben E, Rabe K, Pedersen K, Wu Y, Sicotte H, et al. Prevalence of CDKN2A mutations in pancreatic cancer patients: implications for genetic counseling. Eur J Hum Genet. 2010;19:472-8.
42. Tucker M, Fraser M, Goldstein A, Struewing J, King M, Crawford J, et al. A natural history of melanomas and dysplastic nevi. Cancer. 2002;94:3192-209.
43. Goldstein A, Martinez M, Tucker M, Demenais F. Gene-covariate interaction between dysplastic nevi and the CDKN2A gene in American melanomaprone families. Cancer Epidemiol Biomarkers Prev. 2000;9:889-94.
44. Hussussian C, Struewing J, Goldstein A, Higgins P, Ally D, Sheahan M, et al. Germline p16 mutations in familial melanoma. Nat Genet. 1994;8(1):15-21. (Pubitemid 24274055)
45. American Society of Clinical Oncology policy statement update. Genetic testing for cancer susceptibility. J Clin Oncol. 2003;21(12):2397-406.
46. Robson M, Storm C, Weitzel J, Wollins D, Offit K. American Society of Clinical Oncology policy statement update: genetic and genomic testing for cancer susceptibility. J Clin Oncol. 2010;28:893-901.
47. Kefford R, Newton Bishop J, Bergman W, Tucker M. Counseling and DNA testing for individuals perceived to be genetically predisposed to melanoma: a consensus statement of the melanoma consortium. J Clin Oncol. 1999;17(10):3245-51. (Pubitemid 29470659)
48. Demenais F, Mohamdi H, Chaudru V, Goldstein A, Bishop J, Bishop D, et al. Association of MC1R variants and host phenotypes with melanoma risk in CDKN2A mutation carriers: a GenoMEL study. J Natl Cancer Inst. 2010;102:1568-83.
49. Gerstenblith M, Goldstein A, Tucker M, Fraser M. Genetic testing for melanoma predisposition: current challenges. Cancer Nurs. 2007;30(6):454-61. (Pubitemid 350145157)
50. Hansen C, Wadge L, Lowstuter K, Boucher K, Leachman S. Clinical germline genetic testing for melanoma. Lancet. 2004;5:314-9. (Pubitemid 38541583)
51. de Snoo F, Bergman W, Gruis N. Familial melanoma: a complex disorder leading to controversy on DNA testing. Familial Cancer. 2003;2:109-16. (Pubitemid 37247983)
52. Trepanier A, Ahrens M, McKinnon W, Peters J, Stopfer J, Grumet S, et al. Genetic cancer risk assessment and counseling: recommendation of the National Society of Genetic Counselors. J Genet Couns. 2004;13(2):83-114. (Pubitemid 39024176)
53. Gomy I, Diz M. Hereditary cancer risk assessment: essential tools for a better approach. Hered Cancer Clin Pract. 2013;11(16):1-8.
54. Weitzel J, Blazer K, MacDonald D, Culver J, Offit K. Genetics, genomics, and cancer risk assessment. CA Cancer J Clin. 2011;61:327-59.
55. Caini S, Gandini S, Sera F, Raimondi S, Fargnoli M, Boniol M, et al. Meta-analysis of risk factors for cutaneous melanoma according to anatomical site and clinico-pathological variant. Eur J Cancer. 2009;45:3054-63.
56. Wang W, Niendorf K, Patel D, Blackford A, Marroni F, Sober A, et al. Estimating CDKN2A carrier probability and personalizing cancer risk assessments in hereditary melanoma using MelaPro. Cancer Res. 2010;70(2):552-9.
57. Tsao H, Niendorf K. Genetic testing in hereditary melanoma. J Am Acad Dermatol. 2004;51(5):803-8. (Pubitemid 39516899)
58. Canto M, Harinck F, Hruban R, Offerhaus G, Poley J, Kamel I, et al. International Cancer of the Pancreas Screening (CAPS) Consortium summit on the management of patients with increased risk for familial pancreatic cancer. Gut. 2013;62:339-47.
59. National Comprehensive Cancer Network. Melanoma, version 2.2014. From: http://www.nccn.org/professionals/physician-gls/pdf/melanoma.pdf. Accessed 20 Dec 2013.
60. • Champine M, Kohlmann W, Leachman S. Genetic counseling and testing for hereditary melanoma: an updated guide for dermatologists. Genetics. 2013;S2:004. This article provides a summary of factors associated with melanoma risk assessment including environmental exposure, phenotype, and genetic status. They also discuss the process of genetic counseling and testing for CDKN2A.
61. Center for Disease Control. Skin cancer: prevention. From http://www.cdc.gov/cancer/skin/basic-info/prevention.htm. Accessed 20 Dec 2013.
62. Domchek S, Bradbury A, Garber J, Offit K, Robson M. Multiplex genetic testing for cancer susceptibility: out on the high wire without a net? J Clin Oncol. 2013;31:1267-70.
63. • Aspinwall L, Taber J, Leaf S, Kohlmann W, Leachman S. Melanoma genetic counseling and test reporting improve screening adherence among unaffected carriers 2 years later. Cancer Epidemiol Biomarkers Prev. 2013;22:1687-97. This study assesses the long term effect of CDNK2A genetic counseling and testing on the adherence to clinical and self skin examinations. The results of this study show increased adherence to clinical and self skin examinations in unaffected CDKN2A mutation carriers. The authors conclude that these findings suggest a benefit to genetic counseling and testing for CDKN2A in unaffected relatives of CDKN2A mutation carriers.
64. de Snoo F, Riedijk S, van Mil A, Bergman W, ter Huurne J, Timman R, et al. Genetic testing in familial melanoma: uptake and implications. Psychooncology. 2008;17:790-6.
65. Glanz K, Volpicelli K, Kanetsky PA, Ming ME, Schuchter LM, Jepson C, et al. Melanoma genetic testing, counseling, and adherence to skin cancer prevention and detection behaviors. Cancer Epidemiol Biomarkers Prev. 2013;22:607-14.
66. Aspinwall L, Leaf S, Dola R, Kohlmann W, Leachman S. Patterns of photoprotection following CDKN2A/p16 genetic test reporting and counseling. J Am Acad Dermatol. 2009;60:745-57.